Navigation Links
Chimerix to Present at Upcoming Investor Conferences
Date:6/2/2010

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences:  the 9th Annual Needham Healthcare Conference, 9:00 AM ET, June 9, 2010, and the Jefferies 2010 Global Life Sciences Conference, 12:45 PM ET, June 11, 2010. The conferences are being held in New York City.

Mr. Moch will provide a corporate overview, including an update on the company's clinical-stage candidates, CMX001 and CMX157.  CMX001 is an orally-available, broad-spectrum antiviral being developed for the treatment of dsDNA viral infections in immunocompromised patients.  The compound is in Phase 1 and 2 clinical trials for the treatment of cytomegalovirus and BK virus.  CMX157, a novel lipid conjugate of the drug tenofovir, was created to improve upon the efficacy and safety of the prodrug Viread®, the leading nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV patients.  CMX157, which is in Phase 1 clinical trials, is being developed for its potential to reduce systemic toxicity and enable the development of one-pill once-a-day fixed dose anti-HIV combinations.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respi
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chimerix Initiates Phase 1 Study of CMX157
2. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
3. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
4. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
5. Chimerix Joins International Network of Organizations to Cure Malaria
6. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
7. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
10. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... NEW YORK , Oct. 24, ... formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company ... has implemented a 1-for-50 reverse split of its ... on Friday, October 24, 2014. PlasmaTech,s common stock ... CUSIP number 72754H109 and temporary ticker symbol "ACCPD". ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... 14, 2011 Elsevier, a world-leading provider ... and the Federation of Biochemical Societies (FEBS) announced today ... open access journal. The journal is dedicated to publishing ... both health and disease. , ,In launching this new ...
... CEO of Arteriocyte Cellular Therapies Medical Systems (Arteriocyte) and ... are combining efforts to raise awareness of opportunities for ... They will inspire, celebrate and encourage women to choose ... thrive in STEM fields at a breakfast to be ...
... Amgen (NASDAQ: AMGN ) today announced ... studies were presented at the 53rd Annual Meeting and Exposition ... 2011, in San Diego. Of note, final results from the ... safety and efficacy of Nplate in adults with primary ...
Cached Biology Technology:Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio 2Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio 3Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields 2Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 2Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 3Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 4Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 5Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 6Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 7Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 8Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 9
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/17/2014)... in German . ... drugs. When treating overdoses, doctors are often limited to supportive ... there is a combination of drugs involved. So what can ... his grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute ... answer to this question. "The task was to develop an ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2
... Institute for Medical Research today unveiled a collaboration with ... (MIT) being spearheaded by GlaxoSmithKline (GSK), which aims to ... body,s organs and functions. This initiative is discussed in ... is a powerful collaboration between leaders in the field ...
... from turtles, and scientists who have just sequenced the first ... the shelled creatures, remarkable longevity and ability to survive for ... turtles use to protect their heart and brain from oxygen ... stroke, the researchers said. UCLA conservation biologist ...
... April 9, 2013 Many terrestrial animals are frequently observed ... a lion kill in the Serengeti or a buzzard swooping ... activity in the oceans is especially difficult, and often overlooked ... published in PLOS ONE titled, " White sharks ...
Cached Biology News:Feinstein Institute collaborates with GSK, UPenn, MIT to research body's electrical impulses 2Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 2Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 3Great white sharks 2
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
... Mutation Explorer processes up to 48 lanes, ... Data input can be from either slab ... or primer chemistries. The detection parameters in ... to analyst consistency. We have built ...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: